<p><strong>新的美国实用专利申请针对对昂丹司琼治疗反应显著的患者群体，强化了 Adial 的精准医疗方法</strong></p>
<p>弗吉尼亚州格伦艾伦，2026 年 4 月 29 日（GLOBE NEWSWIRE）-- Adial Pharmaceuticals, Inc.（<strong>NASDAQ: ADIL</strong>）（“Adial” 或 “公司”），一家专注于开发治疗和预防成瘾及相关疾病的临床阶段生物制药公司，今天宣布向美国专利商标局（USPTO）提交了一项新的美国实用专利申请，针对 AD04，该公司主要的研究性基因靶向、5-羟色胺 3 受体拮抗剂，治疗重度饮酒患者的酒精使用障碍（AUD）。一旦专利获得批准，预计将保护 Adial 的核心资产至少到 2045 年。</p>
<p>该申请正在提交优先审查请求，以加快审查进程。优先审查的优势包括显著缩短的审查时间，这将帮助 Adial 获得早期专利性见解，以优化战略并简化审查过程。</p>
<p>Adial 的总裁兼首席执行官 Cary Claiborne 评论道：“随着我们将 AD04 项目推进到下一个临床阶段，这项专利申请代表了加强和延长我们知识产权组合长期价值的重要一步。如果专利获得批准，预计将保护我们的核心资产至少到 2045 年，增强我们潜在商业机会的持久性。”</p>
<p>“该申请反映了我们数据的全面事后分析，并展示了我们在最大化资产价值方面的严谨方法。它增强了我们在接近潜在商业化时的战略定位——既支持早期执行能力，又提高了 AD04 在持续许可讨论中的吸引力。我们相信，延长独占权的潜力显著增强了我们与潜在合作伙伴的谈判地位，并提升了 AD04 在美国和全球商业化机会中的整体价值主张。”</p>
<p><strong>关于 Adial Pharmaceuticals, Inc.</strong></p>
<p>Adial Pharmaceuticals 是一家专注于成瘾及相关疾病治疗开发的临床阶段生物制药公司。该公司的主要研究性新药产品 AD04 是一种基因靶向的 5-羟色胺 3 受体拮抗剂，治疗重度饮酒患者的酒精使用障碍（AUD）。Adial 目前计划为具有通过公司专有诊断基因检测识别的特定靶基因型的受试者开展新的第三阶段临床试验项目。ONWARD 在减少重度饮酒患者饮酒方面显示出良好的结果，没有明显的安全性或耐受性问题。AD04 还被认为有潜力治疗其他成瘾性疾病，如阿片类药物使用障碍、赌博和肥胖。更多信息请访问 www.adial.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本通讯包含某些符合美国联邦证券法定义的 “前瞻性声明”。这些声明基于各种事实，并利用众多重要假设得出，受到已知和未知的风险、不确定性及其他因素的影响，这些因素可能导致实际结果、表现或成就与任何未来结果、表现或成就在实质上存在重大差异。以 “相信”、“期望”、“预期”、“打算”、“项目”、“估计”、“计划” 等词语开头、结尾或以其他方式包含这些词语的声明，或使用 “将”、“应该”、“会”、“可能”、“能够” 等未来或条件动词的声明，通常具有前瞻性特征，而非历史事实，尽管并非所有前瞻性声明都包含上述内容。前瞻性声明包括关于公司针对 AD04 的新专利申请的声明，该专利在获得批准后将保护 Adial 的核心资产至至少 2045 年，继续推进 AD04 项目进入下一个临床阶段，增强和延长公司知识产权组合的长期价值，该专利在获得批准后将增强公司潜在商业机会的持久性，提升公司在接近潜在商业化时的战略定位，通过支持早期执行能力和增加 AD04 在持续许可讨论中的吸引力，延长独占权的潜力显著增强公司与潜在合作伙伴的谈判地位，并提升 AD04 在美国和全球商业化机会中的整体价值主张，以及 AD04 治疗其他成瘾性疾病（如阿片类药物使用障碍、赌博和肥胖）的潜力。此处包含的任何前瞻性声明反映了我们当前的观点，并涉及某些风险和不确定性，包括但不限于我们追求监管战略的能力、推进持续合作讨论的能力、获得产品候选商业化的监管批准或遵守持续监管要求的能力、开发战略合作机会和维持合作关系的能力、获得或维持资助我们研究和开发活动所需的资本或补助的能力、按时完成临床试验并实现预期的结果和利益的能力、与我们推广或商业化特定适应症的产品候选相关的监管限制、市场对我们产品候选的接受程度以及我们产品的成功开发、营销或销售的能力、维持我们的许可协议的能力、继续维护和增长我们的专利资产以及保留关键员工或维持我们的纳斯达克上市的能力。这些风险不应被解释为详尽无遗，并应与我们截至 2023 年 12 月 31 日的 10-K 表格年度报告中包含的其他警示声明一起阅读，以及后续的 10-Q 表格季度报告和向证券交易委员会提交的 8-K 表格当前报告。任何前瞻性声明仅在其最初作出之日有效。除非法律要求，我们不承担公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件、情况变化或其他原因。</p>
<p><strong>联系方式：</strong> Crescendo Communications, LLC</p>
<p>David Waldman / Alexandra Schilt</p>
<p>电话：212-671-1020</p>
<p>电子邮件：adil@crescendo-ir.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjd09UQXdOQ00zTlRjeE56QTBJekl3TVRnek1EST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjd09UQXdOQ00zTlRjeE56QTBJekl3TVRnek1EST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTFiYWE4ODgtZjdhYy00MjNjLWExODMtNTlhNzZjNDllMmU2LTEwMjk4NzItMjAyNi0wNC0yOS1lbg==/tiny/Adial-Pharmaceuticals-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTFiYWE4ODgtZjdhYy00MjNjLWExODMtNTlhNzZjNDllMmU2LTEwMjk4NzItMjAyNi0wNC0yOS1lbg==/tiny/Adial-Pharmaceuticals-Inc.png"/></p>

ADIL

标普生物技术 ETF - SPDR

医疗业 ETF - Vanguard

<p>Adial Pharmaceuticals 已经提交了一项新的美国实用专利申请，针对其主要研究药物 AD04，旨在治疗重度饮酒者的酒精使用障碍（AUD）。如果该专利获得批准，预计将保护公司的核心资产，至少持续到 2045 年。该申请包括加快审查的请求，以增强潜在商业化和许可讨论的战略定位。首席执行官 Cary Claiborne 强调了这一步骤在最大化资产价值和增强与合作伙伴谈判地位方面的重要性</p>

<p><strong>New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial’s precision-medicine approach</strong></p>
<div class="lb-trans"><p><strong>新的美国实用专利申请针对对昂丹司琼治疗反应显著的患者群体，强化了 Adial 的精准医疗方法</strong></p>
</div><p>GLEN ALLEN, Va., April 29, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( <strong>NASDAQ: ADIL</strong>) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the filing of a new U.S. utility application with the United States Patent and Trade Office (USPTO) directed to AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. Once the patent is granted, it is expected to protect Adial’s core assets through at least 2045.</p>
<div class="lb-trans"><p>弗吉尼亚州格伦艾伦，2026 年 4 月 29 日（GLOBE NEWSWIRE）-- Adial Pharmaceuticals, Inc.（<strong>NASDAQ: ADIL</strong>）（“Adial” 或 “公司”），一家专注于开发治疗和预防成瘾及相关疾病的临床阶段生物制药公司，今天宣布向美国专利商标局（USPTO）提交了一项新的美国实用专利申请，针对 AD04，该公司主要的研究性基因靶向、5-羟色胺 3 受体拮抗剂，治疗重度饮酒患者的酒精使用障碍（AUD）。一旦专利获得批准，预计将保护 Adial 的核心资产至少到 2045 年。</p>
</div><p>The application is being filed with a Request for Track One Prioritized examination to expedite examination. The advantages of a Track One Prioritized examination include a substantially shorter examination time that will assist Adial with early patentability insights to refine strategy and a condensed prosecution.</p>
<div class="lb-trans"><p>该申请正在提交优先审查请求，以加快审查进程。优先审查的优势包括显著缩短的审查时间，这将帮助 Adial 获得早期专利性见解，以优化战略并简化审查过程。</p>
</div><p>Cary Claiborne, President and Chief Executive Officer of Adial, commented, “As we advance the AD04 program toward its next clinical phase, this patent application represents a meaningful step in strengthening and extending the long-term value of our intellectual property portfolio. If the patent is granted, it is expected to secure protection for our core assets through at least 2045, reinforcing the durability of our potential commercial opportunity.”</p>
<div class="lb-trans"><p>Adial 的总裁兼首席执行官 Cary Claiborne 评论道：“随着我们将 AD04 项目推进到下一个临床阶段，这项专利申请代表了加强和延长我们知识产权组合长期价值的重要一步。如果专利获得批准，预计将保护我们的核心资产至少到 2045 年，增强我们潜在商业机会的持久性。”</p>
</div><p>“This application reflects a comprehensive post hoc analysis of our data and demonstrates our disciplined approach to maximizing asset value. It enhances our strategic positioning as we approach potential commercialization—both by supporting early enforcement capabilities and by increasing the attractiveness of AD04 in ongoing licensing discussions. We believe the potential for extended exclusivity meaningfully strengthens our negotiating position with prospective partners and enhances the overall value proposition of AD04 for U.S. and global commercialization opportunities.”</p>
<div class="lb-trans"><p>“该申请反映了我们数据的全面事后分析，并展示了我们在最大化资产价值方面的严谨方法。它增强了我们在接近潜在商业化时的战略定位——既支持早期执行能力，又提高了 AD04 在持续许可讨论中的吸引力。我们相信，延长独占权的潜力显著增强了我们与潜在合作伙伴的谈判地位，并提升了 AD04 在美国和全球商业化机会中的整体价值主张。”</p>
</div><p><strong>About Adial Pharmaceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Adial Pharmaceuticals, Inc.</strong></p>
</div><p>Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. Adial is currently planning to conduct a new Phase 3 clinical trial program for the treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, with no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.</p>
<div class="lb-trans"><p>Adial Pharmaceuticals 是一家专注于成瘾及相关疾病治疗开发的临床阶段生物制药公司。该公司的主要研究性新药产品 AD04 是一种基因靶向的 5-羟色胺 3 受体拮抗剂，治疗重度饮酒患者的酒精使用障碍（AUD）。Adial 目前计划为具有通过公司专有诊断基因检测识别的特定靶基因型的受试者开展新的第三阶段临床试验项目。ONWARD 在减少重度饮酒患者饮酒方面显示出良好的结果，没有明显的安全性或耐受性问题。AD04 还被认为有潜力治疗其他成瘾性疾病，如阿片类药物使用障碍、赌博和肥胖。更多信息请访问 www.adial.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the Company’s new patent application for AD04, the patent protecting Adial’s core assets out to at least 2045 once granted, continuing to advance the AD04 program toward its next clinical phase, strengthening and extending the long-term value of the Company’s intellectual property portfolio, the patent reinforcing the durability of the Company’s potential commercial opportunity once granted, enhancing the Company’s strategic positioning as it approaches potential commercialization both by supporting early enforcement capabilities and by increasing the attractiveness of AD04 in ongoing licensing discussions, the potential for extended exclusivity meaningfully strengthening the Company’s negotiating position with prospective partners and enhancing the overall value proposition of AD04 for U.S. and global commercialization opportunities and the potential of AD04 to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.</p>
<div class="lb-trans"><p>本通讯包含某些符合美国联邦证券法定义的 “前瞻性声明”。这些声明基于各种事实，并利用众多重要假设得出，受到已知和未知的风险、不确定性及其他因素的影响，这些因素可能导致实际结果、表现或成就与任何未来结果、表现或成就在实质上存在重大差异。以 “相信”、“期望”、“预期”、“打算”、“项目”、“估计”、“计划” 等词语开头、结尾或以其他方式包含这些词语的声明，或使用 “将”、“应该”、“会”、“可能”、“能够” 等未来或条件动词的声明，通常具有前瞻性特征，而非历史事实，尽管并非所有前瞻性声明都包含上述内容。前瞻性声明包括关于公司针对 AD04 的新专利申请的声明，该专利在获得批准后将保护 Adial 的核心资产至至少 2045 年，继续推进 AD04 项目进入下一个临床阶段，增强和延长公司知识产权组合的长期价值，该专利在获得批准后将增强公司潜在商业机会的持久性，提升公司在接近潜在商业化时的战略定位，通过支持早期执行能力和增加 AD04 在持续许可讨论中的吸引力，延长独占权的潜力显著增强公司与潜在合作伙伴的谈判地位，并提升 AD04 在美国和全球商业化机会中的整体价值主张，以及 AD04 治疗其他成瘾性疾病（如阿片类药物使用障碍、赌博和肥胖）的潜力。此处包含的任何前瞻性声明反映了我们当前的观点，并涉及某些风险和不确定性，包括但不限于我们追求监管战略的能力、推进持续合作讨论的能力、获得产品候选商业化的监管批准或遵守持续监管要求的能力、开发战略合作机会和维持合作关系的能力、获得或维持资助我们研究和开发活动所需的资本或补助的能力、按时完成临床试验并实现预期的结果和利益的能力、与我们推广或商业化特定适应症的产品候选相关的监管限制、市场对我们产品候选的接受程度以及我们产品的成功开发、营销或销售的能力、维持我们的许可协议的能力、继续维护和增长我们的专利资产以及保留关键员工或维持我们的纳斯达克上市的能力。这些风险不应被解释为详尽无遗，并应与我们截至 2023 年 12 月 31 日的 10-K 表格年度报告中包含的其他警示声明一起阅读，以及后续的 10-Q 表格季度报告和向证券交易委员会提交的 8-K 表格当前报告。任何前瞻性声明仅在其最初作出之日有效。除非法律要求，我们不承担公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件、情况变化或其他原因。</p>
</div><p><strong>Contact:</strong> Crescendo Communications, LLC</p>
<div class="lb-trans"><p><strong>联系方式：</strong> Crescendo Communications, LLC</p>
</div><p>David Waldman / Alexandra Schilt</p>
<div class="lb-trans"><p>David Waldman / Alexandra Schilt</p>
</div><p>Tel: 212-671-1020</p>
<div class="lb-trans"><p>电话：212-671-1020</p>
</div><p>Email: adil@crescendo-ir.com</p>
<div class="lb-trans"><p>电子邮件：adil@crescendo-ir.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjd09UQXdOQ00zTlRjeE56QTBJekl3TVRnek1EST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcwOTAwNCM3NTcxNzA0IzIwMTgzMDI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTFiYWE4ODgtZjdhYy00MjNjLWExODMtNTlhNzZjNDllMmU2LTEwMjk4NzItMjAyNi0wNC0yOS1lbg==/tiny/Adial-Pharmaceuticals-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/NTFiYWE4ODgtZjdhYy00MjNjLWExODMtNTlhNzZjNDllMmU2LTEwMjk4NzItMjAyNi0wNC0yOS1lbg==/tiny/Adial-Pharmaceuticals-Inc.png"/></p>

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 | ADIL Stock News

StockTitan

Adial Pharmaceuticals

医疗业 ETF - SPDR

医药突破 ETF - ALPS

标普全球医疗股指数 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

美国制药 ETF - iShares

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

Adial Pharmaceuticals 通过新的美国实用专利申请推进其知识产权组合，旨在获得可能的市场独占权直到 2045 年 | ADIL 股票新闻